Compare LEGH & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEGH | OMER |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.0M | 628.9M |
| IPO Year | 2018 | 2009 |
| Metric | LEGH | OMER |
|---|---|---|
| Price | $20.55 | $8.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $25.00 | ★ $27.50 |
| AVG Volume (30 Days) | 126.6K | ★ 1.5M |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $180,497,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.07 | N/A |
| P/E Ratio | $10.47 | ★ N/A |
| Revenue Growth | ★ 10.25 | N/A |
| 52 Week Low | $18.84 | $2.95 |
| 52 Week High | $29.45 | $13.60 |
| Indicator | LEGH | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 46.20 |
| Support Level | $20.08 | $8.27 |
| Resistance Level | $20.87 | $11.71 |
| Average True Range (ATR) | 0.62 | 0.72 |
| MACD | 0.21 | -0.31 |
| Stochastic Oscillator | 73.33 | 17.04 |
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.